Highlights {#s1}
==========

1.  High level of ROS is associated with migration in colorectal cancer cells.

2.  In highly metastatic colorectal cancer cells, HCT-116 and lovo could form vasculogenic mimicry.

3.  Up-regulation of MMP2 under hypoxia requires ROS generation in colorectal cancer cells.

4.  AAM effectively inhibits migration and VM formation by suppressing ROS/HIF-1*α*/MMP2 axis under hypoxic condition.

Introduction {#s2}
============

Colorectal cancer (CRC) is the third most common cancer and third cause of death in cancer patients worldwide, and the incidence rate is increased in males of the 40--79 age group ([@B50]). Tumor invasion and metastasis are the main cause of death in cancer patients ([@B55]). In traditional opinion, angiogenesis is the main reason for tumor metastasis, therefore, antiangiogenesis drugs were developed and used for treating malignant tumors, including CRC ([@B15]). However, these agents may cause hypoxia, then promotes tumor progression, treatment resistance, and metastasis ([@B26]). Additionally, tumor hypoxia has been demonstrated to promote the formation of vasculogenic mimicry (VM) ([@B6]; [@B11]; [@B32]; [@B59]) VM consists of tumor cells, which link each other and form cell extracellular matrix-rich networks \[peridiodic acid-Schiff (PAS)-positive\]; studies have demonstrated that tumors, including CRC, may develop VM ([@B37]; [@B52]), which is associated with poor prognosis and is partly responsible for resistance to anti-angiogenic agents ([@B38]; [@B62]).

VM formation is induced by many factors. Recent studies revealed that mild hypoxia (1--3% O~2~) increases mitochondrial ROS production ([@B17]; [@B30]). ROS, in turn, promotes ferrous ion (Fe^2+^) oxidation then inhibits the activation of prolyl hydroxylases (PHDs) and hence stabilizes HIF-alpha ([@B17]; [@B41]). Additionally, it has been demonstrated that antioxidants as vitamin C and N-acetylcysteine (NAC) could inhibit HIF-1*α* stabilization then diminishes tumorigenesis in MYC-dependent murine models ([@B14]). Moreover, HIF-1*α* overexpression was reported as a poor prognosis factor for CRC patients ([@B31]).

Although these studies suggest that hypoxia and ROS/HIF-1*α* signaling play important roles in CRC progression, the mechanism of hypoxia mediated CRC progression is not well understood. Furthermore, previous studies confirmed that antiangiogenic agents did not significantly inhibit the formation of VM, and they even induced extracellular matrix-rich tubular network formation ([@B58]). Thus, it is very urgent to probe the mechanism of vasculogenic mimicry and develop related antivascular drugs that specifically target VM.

It has been confirmed that Traditional Chinese Medicine (TCM) could effectively prolong survival time, reduce side effect, enhance treatment effect in cancer patients ([@B36]; [@B45]; [@B33]). Notably, many researchers found that TCM has a potential value in preventing recurrence and metastasis in CRC patients combined with western medicine therapy ([@B61]; [@B49]). Astragalus Atractylodes mixture (AAM) was constructed according to traditional Chinese medicine theories and clinical experience, which consisted of *Astragalus membranaceus Fisch. ex Bunge*. (AMF), *Atractylodes macrocephala Koidz*. (AMK), *Actinidia arguta (Siebold & Zucc.) Planch. ex Miq*. (AAP), *Curcuma aromatica Salisb*. (CAS), *Benincasa hispida (Thunb.) Cogn*. (BHC), and *Ficus pumila L*. (FPL). Many of these herbs have antitumor and antioxidant effect. Astragaloside IV (Astragalus membranaceus extract) suppresses tumor progression through inhibiting Akt/GSK-3*β*/*β*-catenin signaling axis and enhances chemosensitivity *via* targeting caveolin-1 (CAV-1), which led to oxidative stress ([@B27]; [@B64]). *Actinidia arguta* exerts antitumor effect by inhibiting tumor cell proliferation ([@B34]), Additionally, oleanolic acid (*Actinidia arguta (Siebold & Zucc.) Planch. ex Miq*. extraction) has antioxidant activity and attenuates tumor progression *via* inhibiting epithelial--mesenchymal transition (EMT) ([@B1]; [@B60]). Moreover, our previous study found that AAM could effectively prevent CRC progression *via* inhibiting tumor angiogenesis and vasculogenic mimicry (VM) in murine model ([@B44]; [@B24]). However, the details of anti-VM mechanisms of AAM are not well understood until now.

Based on the theory that hypoxia promotes tumor progression *via* activating ROS/HIF-1*α* signaling axis, we speculate that AAM might exert antitumor effect through eliminating ROS production in a tumor hypoxia microenvironment. In this report, the effect of AAM on hypoxia-induced vasculogenic mimicry (VM) was investigated *in vitro*. Moreover, murine lung experimental metastasis model was applied to investigate whether AAM inhibits tumor metastasis. The results showed that AAM suppresses CRC vasculogenic mimicry (VM) formation and migration through inhibiting the ROS/HIF-1*α* pathway in a hypoxic microenvironment. The results of this study may explain the potential antitumor mechanisms of AAM and provide the basis for the clinical treatment of CRC.

Materials and Methods {#s3}
=====================

Reagents and Antibodies {#s3_1}
-----------------------

Reagents were purchased as follows: AAM was purchased from Jiangyin Tianjiang Pharmaceutical Co., Ltd (Jiangsu, China) which has evaluated the quality according to Chinese Pharmacopoeia (CP) (2015); the herb granules are shown in [**Table 1**](#T1){ref-type="table"}. Dulbecco's modified Eagle's medium (DMEM) medium (\#KGM12800, Keygen, Nanjing, China), RPMI-1640 medium (\#KGM31800, Keygen, Nanjing, China), Fetal Bovine Serum (\#100991141, Gibco Life Technologies, Australia), Matrigel matrix (\#356234, BD Bioscience, USA), NAC (\#A725, Sigma-Aldrich, USA), ROS assay kit (\#E004, Nanjing JianCheng Bioengineering Institute), IP lysis buffer (\#P0013, Beyotime Biotechnology), BCA protein Assay kit (\#P0010, Beyotime Biotechnology), CCK-8 assay kit (\#KGA317s, Keygen Biotech, Jiangsu, China), Trizol reagent (sigma, T9424), PrimeScript™ RT Master Mix (\#\#RR036A, Takara, Japan), SYBR Premix Ex Taq (Takara, RR420A, Japan). Antibodies were used as follows: the primary antibodies used for western blot: MMP2 (EPR1184) Rabbit mAb (\#ab92536, Abcam), VE-Cadherin Rabbit mAb (EPR18229) (\#ab205336, Abcam), Eph-receptor A2 (RM-0051-8F21) Rabbit mAb (\#ab73254, Abcam), MMP9 Rabbit pAb (\#A0289, ABclonal), HIF-1alpha (H1alpha67) Mouse mAb (NB100-105, NOVUS), Immobilon western chemilum HRP substrate (ECL, \#KGP1123, KeyGen).

###### 

The compositions of Astragalus Atractylodes mixture (AAM).

  Chinese name   Latin name                             Taxonomic names                                      Weight(g)   Lot number   Part used
  -------------- -------------------------------------- ---------------------------------------------------- ----------- ------------ -----------
  Huang qi       *Astragali radix*                      Astragalus membranaceus Fisch. ex Bunge.             20          18102061     Root
  E zhu          *Curcumae radix*                       Curcuma aromatica Salisb.                            10          18111421     rhizome
  Bai zhu        *Atractylodis macrocephalae rhizoma*   Atractylodes macrocephala Koidz.                     30          18121121     rhizome
  Dong gua zi    *Benincasae semen*                     Benincasa hispida (Thunb.) Cogn.                     10          18061121     seed
  Teng li gen    *Actinidia arguta*                     Actinidia arguta (Siebold & Zucc.) Planch. ex Miq.   30          18061101     Root
  Bi li guo      *Ficus pumila linn*                    Ficus pumila L.                                      15          18082011     fruit

Cell Culture and Treatment {#s3_2}
--------------------------

The human colorectal cancer cell lines HCT-116 and LoVo were purchased from Shanghai Institutes for Biological Sciences (SIBS). HCT116 cells were cultured in DMEM medium, and LoVo cells were incubated in RPMI-1640 medium. All the cell culture medium was supplemented with 10% FBS, 10% penicillin, and streptomycin (100 U/ml). The normoxia cells were placed in 5% CO~2~ and 21% O~2~ cell incubator; hypoxia model was performed in three gas chambers (HF100) (5% CO~2~, 1% O~2~, 94% N~2~). Colorectal cancer cells were seeded in a 6-well plate; when the cell fusion reached about 30%, which were starved for 12 h then treated with 10 mM NAC, with or without AAM (2.5, 5, and 10 mg/ml) for 24 h, cells treated with DMEM medium were used as negative control. Finally, the treated cells were collected for further analysis as described below.

Preparation of Astragalus Atractylodes Mixture {#s3_3}
----------------------------------------------

The herb granules, *Astragalus membranaceus Fisch. ex Bunge* (AMF), Atractylodes macrocephala Koidz. (AMK), Actinidia arguta (Siebold & Zucc.) Planch. ex Miq. (AAP), Curcuma aromatica Salisb. (CAS), Benincasa hispida (Thunb.) Cogn. (BHC), and Ficus pumila L. (FPL) were mixed at a 4:6:3:2:2:3 ratio ([**Table 1**](#T1){ref-type="table"}). Then the herb granules were extracted with 100 ml of ethanol for three times. The extracts were combined and dissolved in 1 ml of methanol. After centrifugation at 1,000 rpm for 5 min, the supernatant was collected and filtrated through a 0.2 μm membrane filter and stored in −20°C before use. The herb granules were purchased from Jiangyin Tianjiang Pharmaceutical Co., Ltd (Jiangsu, China) which has evaluated the quality according to Chinese Pharmacopoeia (CP) (2015).

Extraction and HPLC/MS Analysis {#s3_4}
-------------------------------

The herb granules, *Astragalus membranaceus Fisch. ex Bunge* (AMF), Atractylodes macrocephala Koidz. (AMK), Actinidia arguta (Siebold & Zucc.) Planch. ex Miq. (AAP), Curcuma aromatica Salisb. (CAS), Benincasa hispida (Thunb.) Cogn. (BHC), and Ficus pumila L. (FPL) were mixed at a 4:6:3:2:2:3 ratio and were extracted with 100 ml of ethanol for three times. The extracts were combined and dissolved in 1 ml of methanol. After centrifugation, the supernatant was used for HPLC Q-TOF/MS analyses. The HPLC/MS analyses were carried out on an Agilent 6538 UHD Accurate-Mass Q-TOF LC/MS (Agilent Technologies Inc., USA) with a XSelect HSS T3 C18 column (2.1 × 100 mm, 2.5 μm) eluting with a flow rate of 0.4 ml·min^−1^ over a 19 min gradient as follows: T = 0 min, 5% B; T = 2 min, 5% B; T = 15 min, 95% B; T = 19 min, 95% B (phase A, H~2~O with 0.1% HCOOH; phase B, CH~3~CN with 0.1% HCOOH).

Assay of Intracellular ROS {#s3_5}
--------------------------

A ROS assay kit was used to determine intracellular ROS accumulation. Ten minutes before the end of treatments, cells were washed with PBS then treated with 10 μM DCFH-DA at room temperature for 30 min in the dark, then the cells were harvested, washed, and responded in PBS solution at a density of 5 × 10^6^ cells/ml. The cells were incubated with FITC-conjugated DCF fluorescence then analyzed using FACSAria III flow cytometer. The DCF fluorescence intensity was detected, qualified, and defined as intracellular ROS level.

Cell Viability Assay {#s3_6}
--------------------

The cell viability was measured by CCK-8 assay. Briefly, three groups were conducted; the negative control group was conducted with no cells, the experimental group was conducted with different concentrations (0, 0.5, 1, 2, 4, 6, 8, 12, 16 mg/ml) of AAM, and the positive control was conducted with no drugs. The cells were placed in 96-well plates in a density of 8 × 10^3^ cells/well. After 6 h, cells were incubated with AAM at different concentrations for 24 h. Then the cells were incubated with 10% CCK-8 cell culture medium for 1 h at 37°C. the absorbance of optical density (OD) was measured in a microplate reader at 450 nm (Thermo scientific, Waltham, MA, USA). Cell viability was expressed as a percentage of the control according to the manufacturer's instruction.

Wound Healing Assay {#s3_7}
-------------------

In wound healing assay, cells were plated in 24-well culture plates. After the cells formed a cell monolayer and serum starvation for 12 h, a 20 μl pipet tip was used to scratch a straight line in the center of the well, then cells were treated with medium alone, medium with AAM (2.5 mg/ml), or NAC (10 mM), hypoxia medium, hypoxia medium with AAM (2.5 mg/ml), or NAC (10 mM) for 24 h. To measure the cells' migration ability, the same area of the well was observed in 0 and 24 h after scratching. The cells' scratch area was measured by Image J.

Transwell Migration Assay {#s3_8}
-------------------------

Additionally, the cell migration was measured with Transwell system (\#3422, Corning). Firstly, 5 × 10^4^ cells in 200 μl were loaded in the upper chamber in serum-free medium supplemented with 2.5 mg/ml AAM or 10 mM NAC. Then the chambers were placed into 24-well culture plates which contained 500 μl DMEM/1640 medium with 15% serum. After 24 h of incubation at 37°C under normoxic and hypoxic conditions, the nonmigrating cells were gently removed using cotton swabs, and then the Transwell membrane containing migrated cells was fixed in 95% ethanol for 10 min and stained by 0.1% crystal violet. The number of migrated cells was observed using inverted optical microscope.

VM Formation Assay {#s3_9}
------------------

In the VM formation assay, 96-well plate was coated with 50 μl Matrigel and allowed to gel for 30 min at room temperature; then cells (2 × 10^4^ cells per well) were plated on the surface of Matrigel-coated plates and incubated under hypoxic or normoxic conditions. After 24 h, three random fields of each well were taken using inverted optical microscope (Leica DFC280). The number of tube networks was measured using Image J.

Western Blotting Analysis {#s3_10}
-------------------------

Western blot analysis was performed as previously described ([@B32]). Briefly, cells were lysed using western and IP lysis buffer at 4°C for 30 min and then centrifuged at 12,000 g for 10 min. The supernatant was collected, and the total protein concentration was determined using BCA protein Assay kit. The protein lysates were separated by relative concentrations (8, 10, 12%) of SDS polyacrylamide gels, and then the protein electrophoresis equipment (Bio-Rad, Shanghai, China) was used to transfer the proteins onto the nitrocellulose (NC) membrane. The membranes were blocked with 5% nonfat milk in PBST and then incubated with relative primary antibodies (VE-cadherin, EphA2, HIF-1*α*, MMP2 and MMP9) for 12 h at 4°C. The membranes were washed and incubated with horseradish peroxidase (HRP)-conjugated antimouse or antirabbit IgG for 1 h at 37°C. The protein bands were visualized using ECL.

Quantitative Real-Time PCR {#s3_11}
--------------------------

Total cellular RNA was extracted using Trizol reagent according to the manufacturer's instruction. Reversed transcription was done using PrimerScript™ RT reagent kit (\#RR037A, Takara), and quantitative PCR was performed using ABI 7500 sequence Detector; the primer sequences were listed in [**Table 2**](#T2){ref-type="table"}. Relative mRNA expression levels were analyzed using the 2^−ΔΔCt^ method.

###### 

Primer sequences used in real-time PCR experiment.

  Gene name   Primer sequence (5′ 3′)
  ----------- ---------------------------------
  HIF-1*α*    Forward: CATCTCCATCTCCTACCCACAT
              Reverse: ACTCCTTTTCCTGCTCTGTTTG
              
  MMP2        Forward: ATGACAGCTGCACCACTGAG
              Reverse: AGTTCCCACCAACAGTGGAC
              
  *β*-actin   Forward: AGCGAGCATCCCCCAAAGTT
              Reverse: GGGCACGAAGGCTCATCATT

Murine Lung-Metastasis Model {#s3_12}
----------------------------

Male 6--8-week-old athymic nude mice (n = 15) were purchased from Shanghai Silaike Experiment Animal Co., Ltd (Shanghai, China). Animals were maintained under specific pathogen-free (SPF) conditions. All animal experimental protocols and animal care procedures were approved by the Medicine Animal Ethics Committee of Shanghai University of Traditional Chinese Medicine. All mice were injected with 2 × 10^6^ HCT-116 cells resuspended in 0.2 ml of PBS in the lateral tail vein. The mice were then randomly divided into three treatment groups: control (normal saline, 13.5 ml/kg, i.g.), N-Acetylcysteine (150 mg/kg/d, i.p.), and AAM (16 mg/g, i.g.). The mice were monitored every day and sacrificed after 50 days. Lungs were inspected for metastatic nodules. Organs were fixed overnight at 4°C in formalin for histological analysis. The number of metastatic tumor nodules on the surface of lungs was counted to assess the extent of metastasis.

HE Staining {#s3_13}
-----------

Mice lung specimens were fixed with formalin and embedded with paraffin and then prepared in 5-mm-thick tissue sections. Firstly, hematoxylin was used to stain the sections for 5 min, and the sections were washed with fresh water for 6 min then stained in eosin for 30 s. Five slides of each group were randomly selected and then observed using an inverted phase microscope. Finally, a collaborator who was blinded from the study analyzed the slides results.

Statistical Analysis {#s3_14}
--------------------

Data are expressed as mean ± standard deviation (SD). Statistical analyses of all data were performed with SPSS 18.0 (IBM Corporation, USA). If the data passed the tests for normality and homogeneity of variance, the one-way ANOVA was selected for statistical analysis, otherwise, a nonparametric test was applied. *P* value of ≤0.05 was considered statistically significant.

Results {#s4}
=======

HPLC Analysis of AAM Extract {#s4_1}
----------------------------

High-performance liquid chromatography Q-TOF mass spectrometry has been applied to analyze the chemical composition of the ethanol extract of AAM ([**Figure 1**](#f1){ref-type="fig"}). Nineteen compounds were deduced as chlorogenic acid, isocurcumenol, rutin, calycosin-7-*O*-*β*-D-glucoside, 4′-methoxyisoflavone-7-*O*-*β*-D-glucoside, (6*R*,11*R*)-3-hydroxy-9,10-dimethoxypterocarpan, luteolin, emodin-3-methyl ether, 5-*O*-caffeoyl quinic acid methyl ester, 3-hydroxy-9,10-dimethoxyptercarpan, curcumenol, atractylenolide III, 2-atractylenolide, isorhamnetin, astraisoflavanglucoside-6″-*O*-malonate, ononin, 3*β*-*O*-acetyl ursolic acid, 3*β*-*O*-acetyl oleanolic acid, and *seco* isolariciresinol 9-*O*-*β*-D-glucopyranoside by comparing the fragment ions with those of characteristic components of the herbal preparation reported in literatures ([@B35]; [@B10]; [@B57]; [@B66]) ([**Table 3**](#T3){ref-type="table"}).

![HPLC analysis of AAM extract. Base Peak chromatogram from HPLC Q-TOF/MS analysis of the ethanol extract of AAM (positive ions).](fphar-11-00705-g001){#f1}

###### 

HPLC Q-TOF/MS analysis results for chemical contents in the ethanol extract of AAM (positive ions).

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Peak\   t*~R~* (min)   Compounds name                                        Formula           Calcd. *m*/*z*   Experimental *m*/*z*   Source
  no.                                                                                                                                    
  ------- -------------- ----------------------------------------------------- ----------------- ---------------- ---------------------- --------
  1       4.82           Chlorogenic acid                                      C~16~H~18~O~9~    355.1029         355.1041               FPL

  2       5.84           Isocurcumenol                                         C~15~H~22~O~2~    235.1698         235.1715               CAS

  3       5.93           Rutin                                                 C~27~H~30~O~16~   611.1612         611.1623               BHC

  4       5.97           Calycosin-7-*O*-*β*-D-glucoside                       C~22~H~22~O~10~   447.1291         447.1330               AMF

  5       7.25           4′-Methoxyisoflavone-7-O-β-D-glucoside                C~23~H~26~O~8~    431.1706         431.1384               AMF

  6       7.55           (6*R*,11*R*)-3-Hydroxy-9,10-dimethoxypterocarpan      C~16~H~12~O~6~    301.0712         301.1093               AMF

  7       7.61           Luteolin                                              C~15~H~10~O~6~    287.0556         287.1252               BHC

  8       7.69           Emodin-3-methyl ether                                 C~16~H~12~O~5~    285.0763         285.0784               AAP

  9       8.84           5-*O*-Caffeoyl quinic acid methyl ester               C~17~H~20~O~8~    353.1236         353.2303               FPL

  10      9.37           3-Hydroxy-9,10-dimethoxyptercarpan                    C~17~H~16~O~5~    301.1076         301.1072               AMF

  11      10.52          Curcumenol                                            C~15~H~22~O~2~    235.1698         235.1719               CAS

  12      10.69          Atractylenolide III                                   C~15~H~20~O~3~    249.1491         249.1500               AMR

  13      12.03          2-Atractylenolide                                     C~15~H~20~O~2~    233.1542         233.1561               AMR

  14      13.14          Isorhamnetin                                          C~16~H~12~O~7~    317.0661         317.2098               BHC

  15      14.39          Astraisoflavanglucoside-6′′-*O*-malonate              C~26~H~30~O~13~   551.1765         551.3359               AMF

  16      15.32          Ononin                                                C~22~H~22~O~9~    431.1342         431.3156               AMF

  17      16.48          3*β*-*O*-Acetyl ursolic acid                          C~32~H~50~O~4~    499.3787         499.3794               AAP

  18      16.65          3*β*-*O*-Acetyl oleanolic acid                        C~32~H~50~O~4~    499.3787         499.3789               AAP

  19      18.39          *seco* Isolariciresinol 9-*O*-*β*-D-glucopyranoside   C~26~H~34~O~11~   523.2179         523.3768               FPL
  -----------------------------------------------------------------------------------------------------------------------------------------------

AMF, Astragalus membranaceus Fisch. ex Bunge; CAS, Curcuma aromatica Salisb; AMK, Atractylodes macrocephala Koidz; BHC, Benincasa hispida (Thunb.) Cogn; AAP, Actinidia arguta (Siebold & Zucc.) Planch. ex Miq; FPL, Ficus pumila L.

NAC Inhibit Colorectal Cancer Cell Migration Under Hypoxia Condition {#s4_2}
--------------------------------------------------------------------

To investigate whether ROS affects the migration of colorectal cancer, HCT-116 cells were treated with different concentrations (0, 1.25, 2.5, 5, 10 mM) of NAC and then exposed in normoxia and hypoxia conditions. The migration ability of HCT-116 cells was evaluated using wound-healing assay. As shown in the [**Figure 2**](#f2){ref-type="fig"}, the migration distance of HCT-116 cells is dose dependent on hypoxia condition; however, the migration ability is not affected by the low dose (1.25, 2.5, 5 mM) NAC in normoxia condition. These results suggest that the ROS level regulated the migration ability of colorectal cancer cells under hypoxia condition.

![NAC inhibits colorectal cancer cell migration under hypoxia condition. Wound-healing assay for evaluating the migration ability of HCT-116 cells under normoxia **(A)** and hypoxia condition **(B)**; cells were photographed at 0 and 24 h under 50× magnification. **(C)** The relative scratch area was measured by Image J (normoxia group, \*\**P* \< 0.01; hypoxia group, ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001).](fphar-11-00705-g002){#f2}

Hypoxia Increases ROS Level in Colorectal Cancer Cells and NAC Could Reverse This Phenomenon {#s4_3}
--------------------------------------------------------------------------------------------

To determine whether hypoxia increases the intracellular ROS levels in colorectal cancer cells, firstly, the cells that could form VM were selected from highly metastatic human CRC cell lines (DLD-1, SW620, HCT-116, LoVo). The results showed that HCT-116 and LoVo cells could form VM ([**Figure S1**](#SF1){ref-type="supplementary-material"}). Then, these two cell lines were cultured in hypoxic condition (1% O~2~) for 24 h and then treated with DCFH-DA (10 μM) for 30 min. Finally, the cells were collected to measure the DCF fluorescence intensity using flow cytometry. The results revealed that hypoxia could increase the DCF fluorescence intensity. In addition, the cells that were treated with 10 mM NAC (a known scavenger of ROS) for 24 h could decrease the intracellular ROS level ([**Figures 3A, B**](#f3){ref-type="fig"}). These data showed that hypoxia increases the ROS level in colorectal cancer cells, and NAC could reverse this phenomenon.

![Hypoxia increases the ROS level in colorectal cancer cells and NAC could reverse this phenomenon. The **(A)** HCT-116 and **(B)** LoVo cells were cultured in hypoxic condition (1% O~2~) and treated with NAC for 24 h, then treated with DCFH-DA (10 μM) for 30 min; the DCF fluorescence intensity was measured by flow cytometry.](fphar-11-00705-g003){#f3}

Hypoxia Accelerates Migration and Vasculogenic Mimicry Required ROS Generation {#s4_4}
------------------------------------------------------------------------------

In view of the fact that tumor cell migration is not only critical to cancer metastasis, but also essential for tumor VM ([@B56]; [@B3]), we explored whether hypoxia accelerates migration in colorectal cancer. HCT-116 and LoVo cells were exposed in hypoxic condition (1% O2) for 24 h, and then their migration ability was analyzed using Transwell migration assay and wound-healing assay. As shown in [**Figure S1**](#SF1){ref-type="supplementary-material"}, hypoxia could accelerate migration of both HCT-116 and LoVo cells compared to the normoxia and NAC groups (cells treated with 10 mM NAC). In line with the results obtained by Transwell migration assay, the wound-healing assay also showed that colorectal cancer cells migrated more rapidly in hypoxia than in normoxia, and NAC was able to reverse this phenomenon ([**Figures 4A, B**](#f4){ref-type="fig"} and [**Figure S2**](#SF2){ref-type="supplementary-material"}). In addition, exposure to hypoxia could strongly increase the number of vasculogenic mimicry in colorectal cancer cells, and NAC could significantly inhibit the formation of vasculogenic mimicry ([**Figure 5**](#f5){ref-type="fig"}). Together, these results validate that hypoxia accelerates migration, and vasculogenic mimicry requires ROS generation in colorectal cancer cells.

![Hypoxia accelerates migration and requires ROS generation. Transwell assay was used to evaluate the effect of hypoxia and ROS on migration ability. LoVo **(A)** and HCT-116 **(B)** cells were cultured in hypoxic condition (1% O~2~) and treated with NAC for 24 h; cells on the lower surface of the Transwell membrane were stained with 0.1% crystal violet; the number of migrated cells was photographed under 50× magnification; Data are expressed as mean ± SD, n=3 **(C, D)**. (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001).](fphar-11-00705-g004){#f4}

![Hypoxia accelerates vasculogenic mimicry and requires ROS generation. Vasculogenic mimicry of LoVo **(A)** and HCT-116 **(B)** cells was assayed after NAC treatment for 36 h at normoxia and hypoxia and photographed under 50× (LoVo) and 50× (HCT-116) magnification; data are represented as mean ± SD from at least three experiments. (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001).](fphar-11-00705-g005){#f5}

Up-Regulation of MMP2 Under Hypoxia Requires ROS Generation {#s4_5}
-----------------------------------------------------------

It has been found that several promigratory and provasculogenic genes, such as matrix metalloproteinase (MMPs), epithelial cell kinase (EphA2), and vascular endothelial-cadherin (VE-cadherin), play crucial roles in the formation of VM ([@B19]; [@B48]; [@B21]; [@B51]; [@B23]; [@B7]). These genes have been reported as HIF-1*α*-target genes, and ROS is essential for hypoxia-induced HIF-1*α* stabilization ([@B2]; [@B17]). To investigate whether hypoxia-induced gene expression is also ROS-dependent, the HCT-116 and LoVo cells were treated with NAC in hypoxia, and then the expression level of MMP2, MMP9, VE-cadherin and EphA2 was detected using western-blot. The results showed that NAC markedly blocked hypoxia-stimulated MMP2 expression compared with the untreated group ([**Figures 6A, B**](#f6){ref-type="fig"}), while the expression levels of other genes, including MMP9, VE-cadherin, and EphA2 were not significantly affected ([**Figures 6A, B**](#f6){ref-type="fig"}). Additionally, RT-PCR results also showed that hypoxia-induced MMP2 expression was suppressed largely by treatment with NAC ([**Figures 6C, D**](#f6){ref-type="fig"}). These data revealed that ROS regulates MMP2 expression in CRC cells under hypoxia.

![Up-regulation of MMP2 under hypoxia requires ROS generation. **(A, B)** The expressions of EphA2, VE-cad, MMP2, MMP9 using western blotting analysis after the indicated treatment. Results showed that NAC markedly blocked hypoxia-stimulated MMP2 expression compared with the untreated group; **(C, D)** The expressions of MMP2 using RT-PCR after the indicated treatment (\**P* \< 0.05).](fphar-11-00705-g006){#f6}

AAM Reduces ROS levels and Inhibits Proliferation in Colorectal Cancer Cells {#s4_6}
----------------------------------------------------------------------------

We assessed the influence of AAM on the proliferation of colorectal cancer cells including HCT-116 and LoVo. Marked inhibition of growth was shown in these two cells at 24 h ([**Figures 7A, B**](#f7){ref-type="fig"}). The 50% inhibitive concentration (IC50) of AAM was calculated. Specifically, the IC50 values of AAM for HCT-116 and LoVo were 10 and 6 mg/ml. In addition, to determine whether AAM could inhibit ROS generation, the cells were treated with 2.5 mg/ml AAM for 24 h, and then the ROS level was detected using flow cytometry. As shown in the [**Figures 7C, D**](#f7){ref-type="fig"}, AAM was able to markedly decrease the intracellular ROS level in colorectal cancer cells. These results indicated that AAM could reduce intracellular ROS levels and inhibit proliferation in colorectal cancer cells.

![AAM reduces ROS levels and inhibits proliferation in colorectal cancer cells. HCT-116 **(A)** and LoVo **(B)** cell proliferation was assayed at 24 h after treatment with AAM at different concentrations; cells were treated with 2.5 mg/ml AAM, and the ROS production of HCT-116 **(C)** and LoVo **(D)** cells was evaluated using flow cytometry (\**P* \< 0.05, \*\*\**P* \< 0.001).](fphar-11-00705-g007){#f7}

AAM Inhibits Migration and VM Formation Under Hypoxia {#s4_7}
-----------------------------------------------------

We investigated the effect of AAM on hypoxia-induced migration and VM formation. The wound-healing assay showed that AAM could significantly suppress the hypoxia-induced migration of colorectal cancer HCT-116 and LoVo cells ([**Figures 8A, B**](#f8){ref-type="fig"}). The Transwell migration assay indicated that the hypoxia-induced migration of HCT-116 and LoVo cells was also inhibited by AAM ([**Figures 8C, D**](#f8){ref-type="fig"}). Furthermore, the VM formation assay showed that AAM strongly inhibited the VM formation in a dose-dependent manner in hypoxia and normoxia, and hypoxia could significantly increase the VM formation when compared to the normoxia group ([**Figures 9A, B**](#f9){ref-type="fig"}). Together, these results validate that AAM could inhibit the hypoxia-induced migration and VM formation.

![AAM inhibits migration of HCT-116 and LoVo cells. **(A, B)** Wound-healing assays of HCT-116 and LoVo cells. The cells were treated with medium alone, AAM (2.5 mg/ml), hypoxia medium, hypoxia medium with AAM (2.5 mg/ml) for 24 h. The representative images were shown in magnification of 100×. **(C, D)** Transwell assay was used to evaluate the effect of AAM on HCT-116 and LoVo cell migration. Migrated cells were stained and captured by microscope (50×); cell numbers are compared between groups. (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001).](fphar-11-00705-g008){#f8}

![AAM inhibits VM formation of HCT-116 and LoVo cells. VM formation assay. HCT-116 **(A)** or LoVo **(B)** cells were seed into 96-well plate which had been precoated with matrigel and incubated with AAM (2.5, 5, and 10 mg/ml) under normoxia and hypoxia. The representative images were shown in magnification of 50× (HCT-116) and 50× (LoVo).](fphar-11-00705-g009){#f9}

AAM Inhibits Hypoxia-Induced VM Formation Involving HIF-1*α* and MMP2 {#s4_8}
---------------------------------------------------------------------

As reported above, hypoxia could mediate VM formation *via* the ROS/HIF-1*α*/MMP2 axis. AAM could reduce the hypoxia-induced ROS generation and inhibit VM formation. Therefore, we hypothesize that AAM could reverse this phenomenon *via* the ROS/HIF-1*α*/MMP2 axis under hypoxia. We evaluated the effect of AAM on the expression of HIF-1*α* and MMP2 under normoxia and hypoxia. Western blotting showed that HIF-1*α* and MMP2 protein levels were significantly diminished by AAM in hypoxia ([**Figures 10A, B**](#f10){ref-type="fig"}). RT-PCR showed that AAM also suppressed HIF-1*α* and MMP2 mRNA expression ([**Figures 10C, D**](#f10){ref-type="fig"}). These results revealed that AAM could inhibit hypoxia-induced VM formation involving HIF-1*α* and MMP2.

![AAM inhibits hypoxia-induced VM formation involving HIF-1*α* and MMP2. The HCT-116 **(A)** and LoVo **(B)** cells were treated with different concentrations of AAM under hypoxia and normoxia; the protein expression of HIF-1*α* and MMP2 was detected by western blotting. **(C, D)** The mRNA expression of HIF-1*α* and MMP2 was measured by RT-PCR (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001).](fphar-11-00705-g010){#f10}

AAM Inhibits Metastasis of Colorectal Cancer *In Vivo* {#s4_9}
------------------------------------------------------

We finally evaluated the antitumor effects of AAM in *in vivo* murine lung-metastasis model using NAC as positive control drug. The mice were scarified after tail vein injection for 50 days, and the lung organs were excised. The number of metastatic tumor nodules on the surface of the lungs was counted to assess the extent of metastasis. We found that the number of metastatic tumor nodules tended to be decreased in the NAC group (*P* = 0.073) and significantly decreased in the AAM group (*P* = 0.031) ([**Figure 11A**](#f11){ref-type="fig"}). Then, HE staining was used to determine the metastatic lesions. The results showed that a lot of metastatic lesions were observed in the lung organs with no treatment. However, in mice treated with NAC and AAM, the metastatic lesions decreased markedly ([**Figure 11B**](#f11){ref-type="fig"}).

![AAM inhibits metastasis of colorectal cancer *in vivo*. **(A)** Representative pictures of lungs of NAC, AAM treated and control groups; the number of metastatic tumor nodules on the surface of the lungs was counted (Right side). **(B)** HE staining was used to determine the metastatic lesions. (\**P* \< 0.05).](fphar-11-00705-g011){#f11}

Discussion {#s5}
==========

In 1999, vasculogenic mimicry (VM) was first found by Maniotis ([@B43]) and described as highly invasive melanoma cells that differentiate and obtain endothelial-like characteristic then form vessel-like structures to provide blood supplement for tumor growth, invasion, and metastasis ([@B20]; [@B53]). Thus, the tumor blood supply is not only dependent on angiogenesis, but is also dependent on VM. Additionally, several studies revealed that antiangiogenic drugs could not significantly inhibit VM formation. Moreover, VM is involved in the development of antiangiogenic agents' resistance ([@B58]). Therefore, it is imperative to investigate the relative mechanisms of VM formation and develop target drugs.

Our previous study has demonstrated that VM exists in CRC, and hypoxia-induced EMT promotes VM formation ([@B32]). In this study, we first found colorectal cancer cells HCT-116 and LoVo cells could form VM by screening from four highly invasive CRC cells. As we know, hypoxia is a common feature in solid tumors, which has been reported to mediate a series of tumor biological behaviors, including tumor invasion, epithelial--mesenchymal transition (EMT), angiogenesis, and VM formation ([@B13]; [@B54]; [@B25]; [@B40]). Our study also found that hypoxia could promote the migration and VM formation in CRC. However, the mechanism of hypoxia-induced VM is not very clear. Recently, some studies revealed that under hypoxic condition, hypoxia inducible factor 1*α* (HIF-1*α*) promotes VM formation by activating the expression of prometastatic and provasculogenic genes, such as VE-cadherin, EphA2, MMP2, and MMP9 ([@B19]; [@B21]; [@B39]; [@B59]; [@B12]). Additionally, mild hypoxia (1--3% O~2~) induced reactive oxygen species (ROS) production then stabilizing HIF-1*α* ([@B2]; [@B17]). In the present study, our results showed that hypoxia could increase the ROS production in HCT-116 and LoVo cells, inhibition of ROS production by NAC, the hypoxia-induced VM formation, migration, and MMP2 expression was significantly suppressed. Consequently, we conclude that hypoxia induced VM formation by activating the ROS/HIF-1*α*/MMP2 pathway.

Traditional Chinese Medicine (TCM) has been widely used in China for thousands of years. Currently, several preclinical studies have revealed that TCM can prevent CRC progression and metastasis ([@B9]; [@B5]; [@B49]; [@B47]). In this study, we examined whether AAM could inhibit hypoxia-induced VM formation and explored relative mechanisms. As reported above, AAM is composed of six kinds of Chinese herbs, including *Astragali radix* (AR), *Curcumae radix Atractylodis macrocephalae rhizoma* (AMR), *Actinidia arguta* (AA), *Curcumae radix* (CR), *Benincasae semen* (BS), and *Ficus pumila linn* (FPL), and a series of studies have reported that some of the compounds and active ingredients of AAM could suppress tumor growth ([@B34]; [@B1]; [@B27]; [@B65]). Notably, in these compounds, chlorogenic acid is an antioxidant-rich compound, which could not only effectively scavenge free radicals, but also inhibit cancer-causing pathways ([@B29]). Moreover, it was reported that rutin has effective efficacy in scavenging ROS ([@B16]). Additionally, luteolin was confirmed to have the effect of protecting PC-12 cells from H~2~O~2~ induced injury ([@B63]). Therefore, some of the components of AAM could effectively inhibit cancer-causing pathways and scavenge free radicals.

In this study, we found that AAM significantly inhibits proliferation of both HCT-116 and LoVo cells in a dose-dependent manner. Additionally, AAM could inhibit ROS production by flow cytometry analysis. We next examined the anti-VM effect of AAM using VM formation assay; the results suggested that AAM could suppress VM formation in a dose-dependent manner in hypoxia and normoxia conditions. In addition, the tumor cells that migrate to gather each other is an important step in the process of VM formation ([@B20]; [@B18]). Therefore, a drug that effectively inhibits the tumor cell migration would be a potential agent to suppress VM formation. In this context, the results showed that AAM significantly suppressed hypoxia-induced migration of HCT-116 and LoVo cells.

Previous studies have demonstrated that the hypoxia-induced ROS/HIF-1*α* pathway plays important roles in tumor angiogenesis and VM formation. In this study, we found that the up-regulation of MMP~2~ under hypoxia requires ROS generation. Hence, to gain insight into the mechanistic basis for AAM, the effect of AAM on hypoxia-induced ROS/HIF-1α/MMP~2~ pathway was assessed. Western blotting and RT-PCR demonstrated that AAM effectively down-regulated hypoxia-induced HIF-1*α*, MMP~2~ levels. NAC, a known ROS scavenger, has been reported to inhibit tumorigenesis through diminishing HIF-1*α* levels. In the present study, NAC was used as a positive control, and our results proved that NAC could suppress the hypoxia-induced ROS/HIF-1α/MMP~2~ pathway. It also demonstrated AAM to produce an effect similar to NAC in mouse lung-metastasis model. These results reveal that the VM formation inhibitory effect of AAM on CRC depends on the inhibition of the ROS/HIF-1α/MMP~2~ pathway under hypoxic condition.

Nevertheless, our study has some limitations; previous studies reported that focal adhesion kinase (FAK) directly promotes phosphorylation of VE-cadherin in the residue Y658 of VE-cadherin then promoting vasculogenic mimicry ([@B46]; [@B8]). Additionally, Xin et al. confirmed that EphA2/FAK/Paxillin pathway contributed to VM formation ([@B22]; [@B42]). Furthermore, HIF-1*α* regulates the integrin beta 1 (ITGB1) expression under hypoxia condition ([@B28]), and ITGB1 promotes the formation of VM through regulating the phosphorylation of Y397 of FAK ([@B4]). Therefore, we will deeply explore the potential molecular mechanism of inhibiting VM formation by AAM in subsequent studies.

Conclusions {#s6}
===========

Taken together, these results verified that AAM effectively inhibits migration and VM formation by suppressing the ROS/HIF-1α/MMP2 pathway in colorectal cancer under hypoxic condition, suggesting AAM could serve as a therapeutic agent to inhibit VM formation in human colorectal cancer.
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###### 

Identification of highly metastatic colorectal cancer cells that could form VM. Highly metastatic CRC cells (DLD-1, SW620, HCT-116 and LoVo cells) were seed into 96 well plate which had been pre-coated with Matrigel for 24 hours. The representative images were shown in magnification of DLD-1, SW620, HCT-116 and LoVo cells (50×).

###### 

Click here for additional data file.

###### 

Hypoxia accelerates migration and requires ROS generation. Wound-healing assays of HCT-116 and LoVo cells. The cells were treated with medium alone, NAC (10mmol/L), hypoxia medium, hypoxia medium with NAC (10mmol/L) for 24 h. The representative images were shown in magnification of 100× (A, B); (C and D) the relative scratch area was measured by Image J (\**P* \< 0.05).
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Click here for additional data file.
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